Skip to content
MarketScale
Demo
‹ Back to IndustriesHealthcare

Listen: Real Estate is the New HR with Brandon Tinianov of View

Innovations in workplace and building design can do more than improve productivity. They can also increase a person’s overall health and wellness. Brandon Tinianov, Vice President of Industry Strategy at View, knows this can be difficult to get across to building operators. “Seeing real estate as a medical device is challenging to the typical…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Innovations in workplace and building design can do more than improve productivity. They can also increase a person’s overall health and wellness. Brandon Tinianov, Vice President of Industry Strategy at View, knows this can be difficult to get across to building operators.

“Seeing real estate as a medical device is challenging to the typical wisdom of the workplace environment,” said Brandon. Brandon explains the benefits of dynamic, self-tinting window glass, from energy savings to happier employees.

Much of the conversation in this episode of the Building Management podcast was based around a study released by Jeanne Meister detailing the effects of natural lighting and office views on employees. Click here for a full summary of the study and to learn more about how View Dynamic Glass is promoting productivity and wellness in office spaces across the world.

For the latest news, videos, and podcasts in the Building Management Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @BuildingMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

July partnerships show hospitals aligning without ownership change

July partnerships show hospitals aligning without ownership change

A July McDermott Will & Schulte analysis and four July partnership announcements tracked by Becker’s Hospital Review point to affiliation models that stop short of mergers. St. Christopher’s signed a nonbinding letter of intent with Nemours, Jefferson and Temple; Palomar UC San Diego Health began operating July 1 under a joint powers authority. Several announcements explicitly rule out ownership change, shifting the work to contracts covering governance and other terms.

  • 01In an alliance, the contract does the integrating that an org chart does in a merger: McDermott Will & Schulte says governance design, exclusivity, antitrust review, community commitments and exit rights all have to be settled before signing.
  • 02Purchasing is now explicitly on the table in at least one no-ownership deal, the St. Peter's Health and Billings Clinic-Logan Health talks in Montana, which means shared supply contracts can arrive without a change of control.

Sep 19, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For Healthcare teams

See how Healthcare teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›Marketing Tech›
Keep exploring

More from Healthcare

Healthcare hubMore expert Healthcare coverage.Explore →Executive Thought LeadershipPut clinical leaders on the record.Explore →CooperVisionMedical device storytelling.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512